A model has been developed to predict the risk of hidden lymph node metastasis, helping prevent lymphedema, or arm swelling, after breast cancer surgery while ensuring that opportunities for targeted treatment to reduce the risk of recurrence are not missed.

Sungkyunkwan University School of Medicine's Kangbuk Samsung Hospital said on the 4th that a research team led by Professor Lee Kwan Ho of the Department of Surgery had developed a risk score model to predict the possibility of hidden high-risk lymph node metastasis using the clinical and pathological characteristics of patients with hormone receptor-positive, HER2-negative breast cancer.

During breast cancer surgery, sentinel lymph node biopsy, which removes only some of the axillary lymph nodes, is widely performed to determine whether the cancer has spread to the lymph nodes. In contrast, axillary lymph node dissection, which extensively removes the axillary lymph nodes, is being performed less frequently because of the risk of postoperative complications such as lymphedema.

The problem is that if dissection is omitted, the cancer may be assigned a lower stage based only on the one to three metastases found in the sentinel lymph nodes, even when four or more lymph nodes have actually been affected. This also affects decisions about adjuvant treatment after surgery.

In particular, for hormone receptor-positive, HER2-negative breast cancer, eligibility for abemaciclib, a targeted therapy that lowers the risk of recurrence, may vary depending on the extent of lymph node metastasis. It also affects decisions on whether to administer chemotherapy alongside the results of genetic testing.

The research team analyzed 160 patients with this type of breast cancer who had one to three sentinel lymph node metastases and underwent surgery at Kangbuk Samsung Hospital from 2015 to 2022. The results showed that 17.5% of all patients actually had four or more lymph node metastases. The four types of imaging tests performed before surgery, ultrasound, MRI, PET-CT and CT, alone were not sufficient to significantly predict such hidden high-risk lymph node metastases.

The research team therefore selected five factors, two or more sentinel lymph node metastases, lymphovascular invasion, a tumor size of 2 cm or more, a Ki-67 index of 20% or higher, indicating the degree of cancer cell proliferation, and multiple tumors, and developed a risk score model assigning one point to each factor.

The analysis showed that the low-risk group, with a risk score of 0 to 1, accounted for about 32% of all patients, or 51 people. Among them, only 3.9% had four or more actual lymph node metastases. The negative predictive value, indicating the likelihood that low-risk patients did not have hidden high-risk lymph node metastases, was 96.1%.

In particular, among 43 low-risk patients who were not eligible for abemaciclib treatment under existing criteria, not a single case of four or more actual lymph node metastases was identified. The research team said this confirmed the possibility of reducing the risk that patients who need targeted treatment would be missed because of hidden metastases even if dissection were omitted.

The analysis also found that applying this risk score model could reduce unnecessary axillary lymph node dissections by about 14 cases per 100 patients.

Professor Lee Kwan Ho said, “There were no cases of lymphedema among patients who underwent only sentinel lymph node biopsy. If axillary lymph node dissection can be avoided, it can make a significant difference in patients’ quality of life.”

He added, “This study presents a method that can consider together the possibility of omitting axillary lymph node surgery to reduce postoperative complications such as lymphedema and securing appropriate adjuvant treatment opportunities through accurate staging.”

However, he said, “As this was a retrospective study conducted at a single institution, multicenter external validation involving more patients is needed before it can be applied in actual clinical practice.”

Meanwhile, the findings were published in the latest issue of ‘Annals of Surgical Oncology’, the official journal of the Society of Surgical Oncology in the United States.